Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 10/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175039 | 0.92 | TGFBR1 (0.47) | TGFBR1TBK1KDRBRAFMET | |
| SCHEMBL3943836 | 0.89 | TGFBR1 (0.52) | TGFBR1TBK1 | |
| SCHEMBL4177426 | 0.88 | TGFBR1 (0.49) | TGFBR1TBK1KDRBRAFMET | |
| SCHEMBL3946294 | 0.85 | TGFBR1 (0.49) | TGFBR1TBK1KDRBRAFMET | |
| SCHEMBL3946514 | 0.85 | TGFBR1 (0.51) | TGFBR1KDRBRAFMETHTR1A | |
| SCHEMBL4183785 | 0.83 | TBK1 (0.51) | TGFBR1TBK1 | |
| SCHEMBL4168496 | 0.82 | TGFBR1 (0.47) | TGFBR1 | |
| SCHEMBL3946771 | 0.81 | TGFBR1 (0.53) | TGFBR1KDRBRAFHTR1AHTR1D | |
| SCHEMBL4184901 | 0.80 | TGFBR1 (0.50) | TGFBR1KDRBRAFMETHTR1A | |
| SCHEMBL3953846 | 0.80 | TGFBR1 (0.49) | TGFBR1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885SIGMAR1 2159/4885TBK1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.